文献速递神经肿瘤

高级别胶质瘤的免疫治疗:临床更新与神经外科医生的实践考量

Immunotherapy for High-Grade Gliomas: A Clinical Update and Practical Considerations for Neurosurgeons.
PubMed 文献 · World Neurosurg · 2019-01-22

本综述回顾文献,总结高级别胶质瘤的免疫治疗策略,重点讨论树突状细胞疫苗、肽疫苗、检查点抑制剂和过继性T细胞疗法的已完成及正在进行的临床试验,并阐述免疫治疗面临的挑战及接受此类药物治疗患者的管理细节。尽管免疫治疗尚未完全兑现改善胶质母细胞瘤患者结局的承诺,但对其最终带来持久抗肿瘤反应仍存期待。

要点

  • 高级别胶质瘤标准治疗包括手术切除、化疗和放疗,但多数患者仍在诊断后数年内出现疾病进展并死亡。
  • 免疫治疗在部分血液和实体恶性肿瘤中具革命性,但临床前成功尚未在高级别胶质瘤人体临床试验中重现。
  • 神经外科肿瘤学界需积极参与并跟进免疫治疗药物在高级别胶质瘤患者中的使用。

核心结论

  • 尽管免疫治疗尚未完全兑现改善胶质母细胞瘤患者结局的承诺,但对其最终带来持久抗肿瘤反应仍存期待。
  • 作为神经外科医生,理解标准治疗与高级别脑肿瘤治疗武器库中其他药物之间的复杂相互作用对患者管理至关重要。

研究设计与样本

  • 本综述回顾文献,总结当前高级别胶质瘤的免疫治疗策略。

主要发现

  • 综述重点介绍了研究树突状细胞疫苗、肽疫苗、检查点抑制剂和过继性T细胞疗法的临床前及临床试验。
  • 免疫治疗在部分血液和实体恶性肿瘤中具革命性,但针对高级别胶质瘤模型的临床前成功尚未在人体临床试验中重现。
  • 对免疫治疗这些生物活性治疗的复杂反应可使管理决策复杂化。

局限性

  • 免疫治疗尚未完全兑现改善胶质母细胞瘤患者结局的承诺。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The current standard of care for patients with high-grade gliomas includes surgical resection, chemotherapy, and radiation; but even still most patients experience disease progression and succumb to their illness within a few years of diagnosis. Immunotherapy, which stimulates an anti-tumor immune response, has been revolutionary in the treatment of some hematologic and solid malignancies, generating substantial excitement for its potential for patients with glioblastoma. However, to date, the preclinical success of these approaches against high-grade glioma models has not been replicated in human clinical trials. Moreover, the complex response to these biologically active treatments can complicate management decisions, and the neurosurgical oncology community needs to be actively involved in and up to date on the use of these agents in patients with high-grade glioma. In this review, we discuss the challenges immunotherapy faces for high-grade gliomas, the completed and ongoing clinical trials for the major immunotherapies, and the nuances in management for patients being actively treated with one of these agents. METHODS: We reviewed the literature to summarize the current immunotherapy strategies for high-grade gliomas. RESULTS: Preclinical and clinical trials investigating dendritic cell and peptide vaccines, checkpoint inhibitors, and adoptive T cell therapy are highlighted in this review. CONCLUSIONS: Although immunotherapy has yet to fully fulfill its promise for patients with glioblastoma and improve patient outcomes, there is still excitement that these approaches will eventually lead to durable anti-tumor responses. As neurosurgeons, an understanding of the complex interactions between the standard of care therapies and the other medications used in the treatment arsenal for patients with high-grade brain tumors is crucial to the management of these patients.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Young JS, Dayani F, Morshed RA, et al. Immunotherapy for High-Grade Gliomas: A Clinical Update and Practical Considerations for Neurosurgeons. World Neurosurg. 2019. PMID: 30677574. doi:10.1016/j.wneu.2018.12.222

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。